Mural Oncology (MURA -5.17%), a biotechnology company that previously focused on developing immunotherapy drugs for cancer, announced its second quarter 2025 results on August 4, 2025. The critical news: Mural Oncology fully discontinued all research and development (R&D) programs, including its lead candidate nemvaleukin alfa, and has since begun exploring strategic alternatives such as a sale or liquidation, as announced on April 15, 2025. The quarter saw a net loss per share (GAAP) of ($2.78), far worse ...